CHINA NATIONAL MEDICINES CORPORATION LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.34 CNY | +0.25% |
|
+4.58% | +26.97% |
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.43 for the current year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +26.97% | 3.79B | C+ | ||
| +20.94% | 72.78B | C+ | ||
| -1.26% | 24.24B | C+ | ||
| +5.13% | 8.59B | C | ||
| +8.25% | 8.38B | B | ||
| -19.42% | 8.09B | B- | ||
| +5.56% | 4.81B | B- | ||
| +16.83% | 4.32B | B+ | ||
| -1.83% | 4.05B | B- | ||
| +8.38% | 3.34B | C |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600511 Stock
- Ratings China National Medicines Corporation Ltd.
